blue cross blue shield glp 1 of Massachusetts will stop covering popular GLP-1 weight-loss drugs like Ozempic and Wegovy starting January 1, 2026. The decision comes as the costs for these medications have Why we are changing coverage

In our 1:1 coaching program, clients track protein, fat, fiber, and veggies because these are the guardrails that steer you to the nutrient-dense food that regulates your hormones, including GLP-1

It is well established that lifestyle interventions exert an influence on both weight gain and psychiatric symptomatology [45]

We did not identify a statistically significant increase in stroke risk among GLP-1RA users compared to SGLT2 users

Although Ozempic and Wegovy have taken the media by storm, there are several different forms of GLP-1 agonists on the market including: Liraglutide: Used under the brand names Victoza and Saxenda

I think that potential is there for positive impact, but there are not enough studies yet. Novo Nordisk, which makes Wegovy, doesnt encourage off-label use of its obesity medications